186 related articles for article (PubMed ID: 36187390)
21. High Expression Level of TRIP6 is Correlated with Poor Prognosis in Colorectal Cancer and Promotes Tumor Cell Proliferation and Migration.
Ren H; Su Z; Yang J; Cao J; Zhang Y; Sheng K; Guo K; Wang Y
Biochem Genet; 2024 Mar; ():. PubMed ID: 38430448
[TBL] [Abstract][Full Text] [Related]
22. The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions.
Grunewald TG; Bach H; Cossarizza A; Matsumoto I
Biol Cell; 2012 Nov; 104(11):641-57. PubMed ID: 22804687
[TBL] [Abstract][Full Text] [Related]
23. STEAP4 knockdown inhibits the proliferation of prostate cancer cells by activating the cGMP-PKG pathway under lipopolysaccharide-induced inflammatory microenvironment.
Li W; Yin X; Yan Y; Liu C; Li G
Int Immunopharmacol; 2021 Dec; 101(Pt B):108311. PubMed ID: 34768126
[TBL] [Abstract][Full Text] [Related]
24. Integrated Profiling Identifies
Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
Front Immunol; 2021; 12():722807. PubMed ID: 34646265
[TBL] [Abstract][Full Text] [Related]
25. Ano1 is a Prognostic Biomarker That is Correlated with Immune Infiltration in Colorectal Cancer.
Chen J; Wang H; Peng F; Qiao H; Liu L; Wang L; Shang B
Int J Gen Med; 2022; 15():1547-1564. PubMed ID: 35210827
[TBL] [Abstract][Full Text] [Related]
26. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
27. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
28. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer.
Chen MH; Chang SC; Lin PC; Yang SH; Lin CC; Lan YT; Lin HH; Lin CH; Lai JI; Liang WY; Lu ML; Yang MH; Chao Y
Oncologist; 2019 Dec; 24(12):1534-1542. PubMed ID: 31292272
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of the prognostic and immunotherapeutic implications of STAT family members in human colorectal cancer.
Li D; Jiao Y; Gao W; Hu S; Li D; Zhao W; Chen P; Jin L; Zhao Y; Ma Z; Wu X; Yan Y; Sun W; Du X; Dong G
Front Genet; 2022; 13():951252. PubMed ID: 36061181
[No Abstract] [Full Text] [Related]
30. STEAP proteins: from structure to applications in cancer therapy.
Gomes IM; Maia CJ; Santos CR
Mol Cancer Res; 2012 May; 10(5):573-87. PubMed ID: 22522456
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody to the six-transmembrane epithelial antigen of prostate 4 promotes apoptosis and inhibits proliferation and glucose uptake in human adipocytes.
Qin DN; Kou CZ; Ni YH; Zhang CM; Zhu JG; Zhu C; Wang YP; Zhu GZ; Shi C; Ji CB; Guo XR
Int J Mol Med; 2010 Dec; 26(6):803-11. PubMed ID: 21042773
[TBL] [Abstract][Full Text] [Related]
32. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
[TBL] [Abstract][Full Text] [Related]
33. Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer.
Zhao C; Chen J; Liu Y; Ju S; Wang G; Wang X
Bioengineered; 2021 Dec; 12(2):11648-11661. PubMed ID: 34699318
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Model of Colorectal Cancer Constructed by Eight Immune-Related Genes.
Wen S; He L; Zhong Z; Mi H; Liu F
Front Mol Biosci; 2020; 7():604252. PubMed ID: 33330631
[TBL] [Abstract][Full Text] [Related]
35. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
[No Abstract] [Full Text] [Related]
37. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
38.
Peng L; Chang J; Liu X; Lu S; Ren H; Zhou X; Liu Z; Hu P
Curr Issues Mol Biol; 2021 Oct; 43(3):1529-1547. PubMed ID: 34698109
[TBL] [Abstract][Full Text] [Related]
39. Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase short-chain in Colorectal Cancer.
Wu Q; Yan T; Chen Y; Chang J; Jiang Y; Zhu D; Wei Y
Int J Med Sci; 2021; 18(16):3631-3643. PubMed ID: 34790035
[No Abstract] [Full Text] [Related]
40. Comprehensive Analysis of Prognostic Value and Immune Infiltration of NLRC4 and CASP1 in Colorectal Cancer.
Peng L; Zhu N; Wang D; Zhou Y; Liu Y
Int J Gen Med; 2022; 15():5425-5440. PubMed ID: 35692355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
